Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Athenex to Start US Trial of Oral Docetaxel Product

publication date: Jan 25, 2016
Athenex, a US-China cancer company, received FDA permission to start US clinical trials of its oral formulation of the  chemotherapy docetaxel. Athenex developed Oradoxel using P-glycoprotein (Pgp) pump inhibitor technology that it in-licensed from South Korea's Hanmi Pharma. Oradoxel is the third clinical program developed from the Pgp technology and the company's sixth cancer drug approved for US clinical trials. In October 2015, Athenex struck a deal with Chongqing, China to build two manufacturing plants there. Athenex has also established a joint lab with Hong Kong Polytechnic University, which did much of the work on Oradoxel. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital